Literature DB >> 1718758

Major histocompatibility complex controls clonal proliferation of CD5+ B cells in H-2-congenic New Zealand mice: a model for B cell chronic lymphocytic leukemia and autoimmune disease.

T Okada1, F Takiura, K Tokushige, S Nozawa, T Kiyosawa, H Nakauchi, S Hirose, T Shirai.   

Abstract

By employing H-2-congenic NZB, NZW and (NZB x NZW)F1 mice with either the homozygous H-2d/H-2d, H-2z/H-2z or heterozygous H-2d/H-2z haplotype, we found that in the spleen of all the congenic strains homozygous for H-2z, there were extremely high frequencies of CD5+ B cells. These cells eventually proliferated in an oligoclonal or even monoclonal fashion, and B cell-chronic lymphocytic leukemia (B-CLL) developed in some cases. Because this feature was not observed in H-2d/H-2d homozygotes or H-2d/H-2z heterozygotes, the high CD5+ B cell frequencies are apparently controlled by the homozygosity of a locus or cluster of loci closely linked to H-2z complex of NZW strain. As the CD5+ B cell frequencies in the peritoneal cavity did not differ among the H-2-congenic strains, the frequencies of these cells in the peritoneal cavity and in the spleen appear to be at least in part under separate control. Flow cytometry and Southern blot analyses using an immunoglobulin gene JH probe revealed that the H-2z/H-2z homozygotes, there was a propagation of distinct clonal populations between the spleen and the peritoneal cavity, a finding which suggested that in the major histocompatibility complex (MHC)-related microenvironments for CD5+ B cell propagation differ between the two compartments. All our findings taken together imply that certain different but related MHC haplotypes may predispose either to B-CLL or to autoimmune disease, in close relatives.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1718758     DOI: 10.1002/eji.1830211114

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  5 in total

1.  Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia.

Authors:  Amy J Johnson; David M Lucas; Natarajan Muthusamy; Lisa L Smith; Ryan B Edwards; Michael D De Lay; Carlo M Croce; Michael R Grever; John C Byrd
Journal:  Blood       Date:  2006-05-02       Impact factor: 22.113

Review 2.  Malignancy and systemic lupus erythematosus.

Authors:  Sasha Bernatsky; Ann Clarke; Rosalind Ramsey-Goldman
Journal:  Curr Rheumatol Rep       Date:  2002-08       Impact factor: 4.592

Review 3.  Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?

Authors:  Sujani Yadlapati; Petros Efthimiou
Journal:  Biomed Res Int       Date:  2016-06-27       Impact factor: 3.411

4.  Mixed phenotype lymphomas in thymectomized (SL/KhxAKR/Ms)F1 mice.

Authors:  L M Lu; H Hiai
Journal:  Jpn J Cancer Res       Date:  1999-11

5.  H-2z homozygous New Zealand mice as a model for B-cell chronic lymphocytic leukemia: elevated bcl-2 expression in CD5 B cells at premalignant and malignant stages.

Authors:  H Okamoto; H Nishimura; A Shinozaki; D Zhang; S Hirose; T Shirai
Journal:  Jpn J Cancer Res       Date:  1993-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.